Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
暂无分享,去创建一个
James E. Bradner | Jason S. Carroll | X. Shirley Liu | Clifford A. Meyer | Henry W. Long | Christopher J. Ott | Kornelia Polyak | Housheng Hansen He | Cheng-Ming Chiang | Hao Guo | William T. Barry | Daniel G. Stover | Richard A. Young | Charles Y. Lin | Jun Qi | Yi Liang | Robert M. Witwicki | Christopher Ott | Myles Brown | R. Young | E. Winer | X. Liu | W. Barry | J. Carroll | K. Polyak | M. McKeown | J. Qi | J. Bradner | Shwu‐Yuan Wu | C. Chiang | D. Dillon | S. Huh | M. Janiszewska | H. He | M. Ni | P. Rao | J. Ryan | Shaokun Shu | C. D’Santos | R. Witwicki | Melissa Duarte | H. Mohammed | C. Ott | I. Krop | Yi Liang | L. Anders | Ian E. Krop | Justin M. Roberts | Henry Long | Michalina Janiszewska | Lars Anders | Eric Winer | Shwu-Yuan Wu | D. Stover | Jeremy Ryan | Hisham Mohammed | Hao Guo | Michael McKeown | Antony Letai | Muhammad B Ekram | Deborah Dillon | Jonathan D. Brown | Shaokun Shu | Doris P. Tabassum | Sung Jin Huh | Ernest Doherty | Muhammad B. Ekram | Jonathan Brown | Clive D'Santos | Min Ni | Prakash K. Rao | Melissa Duarte | Ernest Doherty | Guillermo Peluffo | A. Letai | D. Tabassum | Myles A. Brown | X. Liu | J. Ryan | C. Chiang | R. Young | X. Liu
[1] A. Belkina,et al. BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.
[2] E. Winer,et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Bernards,et al. Protein phosphatase 2A regulatory subunits and cancer. , 2009, Biochimica et biophysica acta.
[4] G. Semenza,et al. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.
[5] Weiwei Shi,et al. Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. , 2011, Cancer research.
[6] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[7] K. Matsumoto,et al. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer , 2013, Oncogene.
[8] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[9] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[10] William B. Smith,et al. Genome-wide localization of small molecules , 2013, Nature Biotechnology.
[11] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[12] Paul Ellis,et al. Dissecting the heterogeneity of triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[14] Carlos Caldas,et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. , 2013, Cell reports.
[15] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[16] David A. Orlando,et al. Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.
[17] Jason J Burbank,et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. , 2014, The Journal of clinical investigation.
[18] Gordon B Mills,et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.
[19] Łukasz M. Boryń,et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.
[20] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[21] Shwu‐Yuan Wu,et al. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.
[22] Mithat Gönen,et al. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.
[23] Mark A. Dawson,et al. BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.
[24] Gedge D. Rosson,et al. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. , 2013, Cell stem cell.
[25] W. Hahn,et al. Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.
[26] F. Rojo,et al. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects , 2015, Oncotarget.
[27] Amber L. Couzens,et al. The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data , 2013, Nature Methods.
[28] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[29] A. Letai,et al. BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.
[30] Cole Trapnell,et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.
[31] Charles Y. Lin,et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.
[32] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[33] Charles Y. Lin,et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.
[34] R. Young,et al. Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.
[35] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[36] Andrew L. Kung,et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. , 2014, Molecular cell.